Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Total Current Liabilities (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Total Current Liabilities data on record, last reported at $11.4 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 18.67% year-over-year to $11.4 million; the TTM value through Dec 2025 reached $11.4 million, down 18.67%, while the annual FY2025 figure was $11.4 million, 18.67% down from the prior year.
  • Total Current Liabilities reached $11.4 million in Q4 2025 per LCTX's latest filing, up from $9.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $25.1 million in Q2 2022 and bottomed at $6.6 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $15.0 million, with a median of $15.3 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: surged 271.44% in 2022, then crashed 36.02% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $8.8 million in 2021, then surged by 115.91% to $19.0 million in 2022, then decreased by 5.38% to $18.0 million in 2023, then decreased by 22.18% to $14.0 million in 2024, then dropped by 18.67% to $11.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $11.4 million in Q4 2025, $9.4 million in Q3 2025, and $10.8 million in Q2 2025.